Elza C. De Bruin

Oncology R&D
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer.

Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer.

Journal: medRxiv : the preprint server for health sciences

Published: June 05, 2026

Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.

Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 08, 2025

Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer.

Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 24, 2024

The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer.

The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer.

Journal: NPJ breast cancer

Published: September 17, 2024

A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer.

A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer.

Journal: Future oncology (London, England)

Published: September 16, 2024

Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.

Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.

Journal: Targeted oncology

Published: September 11, 2024

Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer.

Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer.

Journal: JCO precision oncology

Published: May 01, 2024

mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors.

mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors.

Journal: Cancer research communications

Published: March 28, 2024

Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.

Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.

Journal: British journal of cancer

Published: September 25, 2023

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Journal: NPJ breast cancer

Published: September 19, 2023

Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.

Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.

Journal: Nature communications

Published: September 12, 2023

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.

Journal: The New England journal of medicine

Published: May 31, 2023

Showing 1-12 of 36

Last Updated: 09/26/2026